Q-omics provides the consensus-scored PTCHD3P2 profile across patient tissues and cancer cell-line models. PTCHD3P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PTCHD3P2 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, PTCHD3P2 RNA expression shows 17,254 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, COAD, and THYM as cancer lineages where PTCHD3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTCHD3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTCHD3P2 survival associations across molecular data types. PTCHD3P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTCHD3P2 RNA expression–survival associations across cancer types. High PTCHD3P2 expression shows unfavorable associations in UVM and UCEC, but favorable associations in UCS, HNSC, LUSC and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for PTCHD3P2 RNA expression.
This table summarizes PTCHD3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PTCHD3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTCHD3P2 shows lower tumor expression in KIRP and higher tumor expression in COAD, LIHC, LUAD, PAAD and THCA. The COAD box plot shows higher PTCHD3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.337, t-test p = .011).
This table shows molecular features associated with PTCHD3P2 in patient tissues and cancer cell lines. In patient samples, PTCHD3P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
